Table 2.
Comparison of β-cell function and insulin sensitivity, lipid profiles, and lymphocyte subsets of RPL patient with IR and non-IR.
| Non-IR (n = 33) | IR (n = 56) | P-value | ||
|---|---|---|---|---|
| β-cell function and insulin sensitivity | HOMA-IR | 1.3 ± 0.5 | 2.6 ± 1.5 | <0.0001* |
| HOMA-β | 92.5 ± 33.4 | 144.2 ± 69.2 | 0.0002* | |
| ΔI30/ΔG30 | 20.7 ± 18.1 | 21.6 ± 10.7 | 0.78 | |
| InsAUC30/GluAUC30 | 36.2 ± 16.8 | 46.6 ± 21.1 | 0.03* | |
| InsAUC120/GluAUC120 | 49.8 ± 21.0 | 67.4 ± 30.0 | 0.007* | |
| Matsuda index (ISIM) | 8.0 ± 3.0 | 4.9 ± 2.3 | <0.0001* | |
| DI | 75.7 ± 20.4 | 62.0 ± 20.1 | 0.005* | |
| DI30 | 261.0 ± 96.1 | 194.7 ± 72.7 | 0.0009* | |
| DI120 | 358.1 ± 117.2 | 275.8 ± 81.9 | 0.0005* | |
| Lipid profiles | TCH (mmol/L) | 4.4 ± 0.7 | 4.4 ± 0.9 | 0.97 |
| TG (mmol/L) | 0.8 ± 0.4 | 1.1 ± 0.6 | 0.025* | |
| LDL-C (mmol/L) | 2.8 ± 0.3 | 2.9 ± 0.4 | 0.35 | |
| HDL-C (mmol/L) | 1.3 ± 0.3 | 1.4 ± 0.4 | 0.17 | |
| HCY (µmol/L) | 9.5 ± 2.8 | 8.6 ± 2.3 | 0.20 | |
| TSH (mIU/L) | 1.8 ± 0.9 | 2.2 ± 1.0 | 0.11 | |
| FT3 (pmol/L) | 5.0 ± 0.4 | 5.0 ± 0.6 | 0.97 | |
| FT4 (pmol/L) | 16.2 ± 2.1 | 17.2 ± 2.3 | 0.12 | |
| Lymphocyte subsets | CD3+ cells (%) | 70.1 ± 9.7 | 67.6 ± 8.4 | 0.22 |
| CD3+CD4+ cells (%) | 36.1 ± 6.9 | 34.9 ± 6.4 | 0.43 | |
| CD3+CD8+ cells (%) | 28.1 ± 7.6 | 26.9 ± 6.0 | 0.39 | |
| CD3+CD4+/CD3+CD8+ cell Ratio | 1.4 ± 0.5 | 1.4 ± 0.4 | 0.89 | |
| CD16+CD56+ cells (%) | 16.6 ± 9.1 | 18.7 ± 8.5 | 0.27 | |
| CD19+ cells (%) | 11.2 ± 3.0 | 11.9 ± 3.8 | 0.76 |
IR, insulin resistance; non-IR, none insulin resistance; HOMA-IR, homeostasis model assessment for insulin resistance; HOMA-β, homeostasis model assessment of β cell function; DI, disposition index, representing an adjusted insulin sensitivity; TCH, total cholesterol, TG, triglyceride; LDL, low density lipoprotein-cholesterol; HDL, high density lipoprotein-cholesterol; HCY, homocysteine; TSH, thyrotropin; FT3, free triiodothyronin; and FT4, free thyroxine. *Significant difference between the two groups.